Hypaque 76 is a radiopaque contrast agent supplied as a 76 percent sterile aqueous solution providing 66 percent (w/v) diatrizoate meglumine and 10 percent (w/v) diatrizoate sodium.

GE Healthcare has discontinued Hypaque 76 for unknown reasons.

Gastrografin® is a water-soluble iodinated radiopaque contrast agent for x-ray examinations of the esophagus, stomach, proximal small intestine, colon and is also used for bowel visualization in abdominal computer tomograms.
The high opacification and delineation after oral or rectal administration is caused by a low absorption of the intact gastrointestinal tract. However, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution.

MD-Gastroview® (solution of 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium Solution) is an iodinated oral contrast agent with lemon-vanilla-flavor. MD-Gastroview® is water-soluble and suitable for oral or rectal administration.
MD-Gastroview® is indicated for radiographic and CT examination of the esophagus, stomach, proximal small intestine and colon, when a barium sulfate suspension is not feasible or contraindicated.
A usual adult dose for abdominal CT is 240 mL of a solution prepared by diluting 25 mL (9.17 g iodine) to one liter with tap water. Less dilute solutions [up to 77 mL (28.26 g iodine) diluted to one liter with tap water] may be used when indicated. The dose is administered orally about 15 to 30 minutes prior to imaging in order to permit the contrast medium to reach the pelvic loops.

RenoCal®-76 (diatrizoate meglumine and diatrizoate sodium) was used as a contrast agent. Bracco Diagnostics, Inc. stated that the production of Renocal-76 has been discontinued due to reduced demand.

Renografin®-60 (diatrizoate meglumine and diatrizoate sodium) was used as a radiopaque contrast agent. Bracco Diagnostics, Inc. states that the production of Renografin-60 has been discontinued due to reduced demand.